Kite, a Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer

Kite to Receive Exclusive License to Leverage Sangamo's Gene Editing Technology in Allogeneic and Autologous Cell Therapy Programs in Oncology SANTA MONICA, Calif. and RICHMOND, Calif., Feb. 22, 2018 -- (Healthcare Sales & Marketing Network) -- Kite, a... Biopharmaceuticals, Oncology, Licensing Sangamo Therapeutics, Kite, Gilead, zinc finger nuclease

http://salesandmarketingnetwork.com/news_release_bs.html?ID=2043541

Source: HSMN NewsFeed - February 22, 2018 Category: Pharmaceuticals Source Type: news